Abstracts

ELITE CONTROLLERS: A MODEL FOR A FUNCTIONAL CURE OF HIV-1 INFECTION

HIV integrates into the host genome to establish life-long infection, requiring indefinite antiretroviral therapy. The development of novel strategies that induce a long-term, drug-free remission of HIV-1 infection has evolved as one of the highest-priority objectives for the HIV research community. Intriguingly, such a long-term, drug-free remission or ‘functional cure’ of HIV-1 infection is naturally…

NOVEL FINDINGS OF NEURONAL MODULATION OF HIV EXPRESSION IN MICROGLIA

Although cART dramatically lowers the levels of viral RNA in the brain, it does not reduce the incidence of HIV-associated neurocognitive disorders (HAND), which still develop in up to 50% of HIV patients. Initial studies indicated paradoxically that the development of HAND correlates strongly with systemic inflammation and CNS inflammation, but did not correlate with…

ROLE OF CNS CD4 T CELLS AND MACROPHAGES IN SIV NEUROPATHOGENESIS AND RESERVOIRS

While the use of combination antiretroviral therapy effectively suppresses systemic viral replication, neurocognitive disorders remain a persistent clinical problem. Therefore, the use non-human primate models are necessary to study mechanisms of neuropathogenesis. Simian immunodeficiency virus (SIV)–infected non-human primates can serve as a relevant model for AIDS neuropathogenesis. The current SIV-induced encephalitis (SIVE)/neuroAIDS models are generally…

MYELOID CNS HIV RESERVOIRS…THE DEBATE CONTINUES

Gallant efforts are ongoing to achieve sustained antiretroviral therapy (ART)–free HIV remission. With the exception of 2 stem-cell transplantation cases and the few instances of natural control, this has been proven challenging. Recent advances have highlighted the importance of myeloid reservoirs as sanctuaries of HIV persistence and therefore may partially be responsible for viral recrudescence…

SUSTAINED DELIVERY AND LONG-ACTING AGENTS FOR PREVENTION OF HIV

The approval, availability, and scale-up of oral preexposure prophylaxis (PrEP) for HIV continues to impact on population-level HIV incidence around the world, shining a spotlight on the potential of primary prevention in ending the HIV epidemic. Yet, for many reasons daily oral PrEP is not and may never be feasible for every individual and every…

INTRINSIC RESISTANCE OF RESERVOIR CELLS TO IMMUNE KILLING

Cytotoxic T-cell (CTL) responses against HIV play a critical role in partially controlling viral replication in the absence of antiretroviral therapy (ART) but fail to eradicate HIV reservoirs. The ability of these reservoirs to persist on ART, despite CTL, is generally attributed to 3 primary factors: i) viral latency – a barrier to detection by…

ARVs AND ART FOR NEWBORNS AND INFANTS: A LAST FRONTIER

This state-of-the-ART talk on antiretroviral drugs and antiretroviral treatment in neonates and infants will focus on: • The considerations when evaluating the safety and dosing of new ARVs in infants and young children • The additional considerations when treating premature infants with antiretroviral drugs for prophylaxis or treatment • The evolving paradigm around the use…